- Adjusted pre-tax profit surges 41%
- Strong performance from food intolerance division
- Positive about future prospects

Medical diagnostics company Omega reported a surge in full-year adjusted pre-tax profit after a robust performance from its food intolerance division and said it remains positive about future trading.

Adjusted pre-tax profit soared 41% to £1.10m for the year ended March 31st while turnover firmed 3% to £11.6m. The Scotland-based group said it was encouraged by prospects for its Visitect CD4 HIV testing kit which is now well into its field trials.

Adjusted earnings per shares fell to 1.2p from 1.3p previously. Gross profit for the period rose 5% to £7.4m.

Among its main divisions, Food Intolerance revenue rose 18% to £5.18m, Allergy and autoimmune revenue slipped 5% to £3.96m while Infectious disease/other revenue dropped 10% to £2.45m.

Chairman David Evans said: "Our future landscape is brightened, as well as dominated, by the prospects for our Visitect CD4 test, which is now well into its field trials. However, we all have a dislike for complete uncertainty and that is our challenge in being able to set our budgets for the current year in relation to both the timing and quantum of CD4 revenues.

"We will make significant progress this year in terms of gaining market acceptance for CD4 and I believe the prospects for the group remain positive."


CJ

Related share prices
Omega Diagnostics Group (ODX) share price